The portfolio will be an optimal mix of large, mid and small capitalization companies. The Investment Manager shall make investments after undertaking detailed fundamental research on companies, taking into account both qualitative and quantitative factors
The Investment Objective is to invest in equity and equity related instruments primarily focused on the healthcare ecosystem in India.
Returns as on 2025-12-31
| Period | Strategy | Benchmark | Outperformance |
|---|---|---|---|
| 1 MONTH | -4.31% | -0.24% | -4.07% |
| 3 MONTHS | 3.27% | 5.02% | -1.75% |
| 6 MONTHS | 9.98% | 1.63% | 8.35% |
| 1 YEAR | 12.47% | 7.63% | 4.84% |
| 2 YEAR | 26.69% | 11.64% | 15.05% |
| 3 YEAR | 30.96% | 16.40% | 14.56% |
| SINCE INCEPTION | 20.37% | 15.27% | 5.10% |
| Year | Return |
|---|---|
| CY 2025 | 12.47% |
| CY 2024 | 42.75% |
| CY 2023 | 39.92% |
| CY 2022 | -6.07% |
| CY 2021 | 17.97% |
| Year | Return |
|---|---|
| FY 26_YTD | 19.83% |
| FY 25 | 36.88% |
| FY 24 | 50.18% |
| FY 23 | -5.01% |
| FY 22 | 7.15% |
| FY 21 | -0.99% |
Past performance is not indicative of future results. Returns are subject to market risks.
Fund Manager
Mr. Aditya Khemka has 18 years of experience in healthcare businesses and investments across the US, EU, Latin America, and India. He holds an MSc. in Finance, a PGDM from MDI Gurgaon, CIIA (UK), and CFA from ICFAI. At DSP, he formulated and executed a product strategy that achieved alpha over the benchmark within 18 months, with low churn and the highest Sharpe ratio among peers.
AMC: 2.5%
AMC: 1.5%
Hurdle: 8%
Profit Sharing: 20%
Year 1: 2%
Year 2: 1%
Year 3: 0%
* Returns are as on31st December 2025 , * Returns over a 1 year period are annualized * Returns are calculated using the Time Weighted Rate of Return (TWRR) method and as provided by the respective AMCs. *ND (No Data) , * NA(Not Applicable) * Returns of the respective Benchmark Indices used are tabulated above. Benchmark(s) given are as per SEBI circular no. SEBI/HO/IMD/IMD-PoD-2/P/CIR/2022/172 dated December 16, 2022 and the APMI circular no. APMI/2022-23/02 dated 23rd March,2023 and Revised Annexure-1
This profile is provided for general informational purposes only and is based on publicly available information. While reasonable care is taken, the content may not always reflect the latest updates.
Nothing on this page constitutes investment, financial, or legal advice. Investment decisions should be made after consulting a qualified advisor and reviewing official scheme documents.
Affluense AI – Smarter Insights. Stronger Relationships with Affluents.
Last Updated: January 2026 · Published by Affluense AI (affluense.ai)
